NASDAQ:DARE

Daré Bioscience Stock Forecast, Price & News

$1.60
+0.06 (+3.90 %)
(As of 08/2/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.52
$1.63
50-Day Range
$1.21
$2.00
52-Week Range
$0.94
$3.85
Volume3.49 million shs
Average Volume4.89 million shs
Market Capitalization$78.96 million
P/E RatioN/A
Dividend YieldN/A
Beta1.75
30 days | 90 days | 365 days | Advanced Chart
Receive DARE News and Ratings via Email

Sign-up to receive the latest news and ratings for Daré Bioscience and its competitors with MarketBeat's FREE daily newsletter.


Daré Bioscience logo

About Daré Bioscience

Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, focuses on developing and marketing products for women's health in the United States. The company develops therapies in the areas of contraception, fertility, and sexual and vaginal health. Its products in advanced clinical development include DARE-BV1, a bioadhesive hydrogel formulated with clindamycin phosphate 2% to treat bacterial vaginosis in a single administration that has completed Phase 3 clinical trials; Ovaprene, a hormone-free monthly vaginal contraceptive; and Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder. The company's Phase 1-ready products are DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone therapy; DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar vaginal atrophy in patients with hormone-receptor positive breast cancer; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and broader luteal phase support as part of an in vitro fertilization treatment plan. Its products in pre-clinical stage include DARE-LARC1, a combination product designed to provide reversible contraception; ORB-204 and ORB-214, an injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-RH1, a non-hormonal contraception for men and women. The company is headquartered in San Diego, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.69 out of 5 stars

Medical Sector

952nd out of 2,226 stocks

Pharmaceutical Preparations Industry

459th out of 870 stocks

Analyst Opinion: 3.5Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Daré Bioscience (NASDAQ:DARE) Frequently Asked Questions

Is Daré Bioscience a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Daré Bioscience in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Daré Bioscience stock.
View analyst ratings for Daré Bioscience
or view top-rated stocks.

What stocks does MarketBeat like better than Daré Bioscience?

Wall Street analysts have given Daré Bioscience a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Daré Bioscience wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Daré Bioscience?

Daré Bioscience saw a increase in short interest in the month of July. As of July 15th, there was short interest totaling 5,250,000 shares, an increase of 126.3% from the June 30th total of 2,320,000 shares. Based on an average daily trading volume, of 7,590,000 shares, the short-interest ratio is currently 0.7 days. Approximately 11.4% of the shares of the company are short sold.
View Daré Bioscience's Short Interest
.

When is Daré Bioscience's next earnings date?

Daré Bioscience is scheduled to release its next quarterly earnings announcement on Wednesday, August 11th 2021.
View our earnings forecast for Daré Bioscience
.

How were Daré Bioscience's earnings last quarter?

Daré Bioscience, Inc. (NASDAQ:DARE) released its earnings results on Thursday, May, 13th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.07.
View Daré Bioscience's earnings history
.

How has Daré Bioscience's stock price been impacted by Coronavirus (COVID-19)?

Daré Bioscience's stock was trading at $1.01 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, DARE stock has increased by 58.4% and is now trading at $1.60.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for DARE?

3 Wall Street analysts have issued 12-month price objectives for Daré Bioscience's shares. Their forecasts range from $5.00 to $11.00. On average, they expect Daré Bioscience's share price to reach $8.00 in the next twelve months. This suggests a possible upside of 400.0% from the stock's current price.
View analysts' price targets for Daré Bioscience
or view top-rated stocks among Wall Street analysts.

Who are Daré Bioscience's key executives?

Daré Bioscience's management team includes the following people:
  • Ms. Sabrina Martucci Johnson, Pres, CEO, Sec. & Director (Age 54, Pay $563.74k)
  • Ms. Lisa Walters-Hoffert, Chief Financial Officer (Age 62, Pay $400.32k)
  • Mr. John A. Fair, Chief Strategy Officer (Age 50, Pay $453.61k)
  • Mr. Mark Walters, VP of Operations (Age 66)
  • Ms. MarDee J. Haring-Layton, VP of Accounting & Fin. (Age 45)
  • Dr. David Friend, Chief Scientific Officer
  • Ms. Mary Jarosz, Global Head of Regulatory Affairs
  • Mr. John Katsilometes, Controller

Who are some of Daré Bioscience's key competitors?

What other stocks do shareholders of Daré Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Daré Bioscience investors own include FuelCell Energy (FCEL), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), Vaxart (VXRT), Tonix Pharmaceuticals (TNXP), Matinas BioPharma (MTNB), Novavax (NVAX), Gilead Sciences (GILD), SCYNEXIS (SCYX) and Sorrento Therapeutics (SRNE).

What is Daré Bioscience's stock symbol?

Daré Bioscience trades on the NASDAQ under the ticker symbol "DARE."

How do I buy shares of Daré Bioscience?

Shares of DARE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Daré Bioscience's stock price today?

One share of DARE stock can currently be purchased for approximately $1.60.

How much money does Daré Bioscience make?

Daré Bioscience has a market capitalization of $78.96 million. The biotechnology company earns $-27,400,000.00 in net income (profit) each year or ($0.91) on an earnings per share basis.

How many employees does Daré Bioscience have?

Daré Bioscience employs 16 workers across the globe.

What is Daré Bioscience's official website?

The official website for Daré Bioscience is www.darebioscience.com.

Where are Daré Bioscience's headquarters?

Daré Bioscience is headquartered at 3655 NOBEL DRIVE SUITE 260, SAN DIEGO CA, 92122.

How can I contact Daré Bioscience?

Daré Bioscience's mailing address is 3655 NOBEL DRIVE SUITE 260, SAN DIEGO CA, 92122. The biotechnology company can be reached via phone at 858-926-7655 or via email at [email protected]


This page was last updated on 8/2/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.